Literature DB >> 16770615

Gastrointestinal manifestations in Hungarian scleroderma patients.

Szilvia Szamosi1, Zoltán Szekanecz, Gabriella Szucs.   

Abstract

Systemic sclerosis (SSc) is a chronic connective tissue disease characterized by fibrosis and destruction of the microvasculature. Increased deposition of collagen and other extracellular matrix components affects not only the skin but most of the internal organs including lungs, heart, kidneys and the gastrointestinal (GI) tract. Within the GI tract, esophageal involvements are most frequently seen features. However, abnormalities in the small intestine, colon and anorectum may also occur. A retrospective study was performed to investigate the frequency and clinical relevances of GI involvement in patients with SSc. Charts of altogether 246 SSc patients were reviewed. This patient population included 40 males and 206 females, with a mean age of 54.2 years. In general, 176 of 246 patients (71.5%) had GI symptoms. Esophageal involvement including gastro-esophageal reflux disease (GERD), aperistalsis, pseudodiverticuli, etc. was the most common (62.6%). In addition, diseases of the stomach (31.7%), dysfunctions of the colon and anorectum (11.4%), as well as sclerosis of the biliary tract and other pancreato-biliary disorders (9.8%) also occurred. Diarrhea and malabsorption resulted in cachexia and other secondary complications leading to death in two cases. Our results support that GI manifestations are rather common in SSc. Apart from the esophagus, other GI complications in SSc are usually mild, however, early recognition is necessary to improve quality of life.

Entities:  

Mesh:

Year:  2006        PMID: 16770615     DOI: 10.1007/s00296-006-0146-z

Source DB:  PubMed          Journal:  Rheumatol Int        ISSN: 0172-8172            Impact factor:   2.631


  20 in total

Review 1.  Gastrointestinal manifestations of scleroderma.

Authors:  S Rose; M A Young; J C Reynolds
Journal:  Gastroenterol Clin North Am       Date:  1998-09       Impact factor: 3.806

Review 2.  [Clinical aspects, pathophysiology, diagnosis and therapy of gastrointestinal manifestations of progressive systemic scleroderma].

Authors:  C Folwaczny; W Voderholzer; R L Riepl; N Schindlbeck
Journal:  Z Gastroenterol       Date:  1996-08       Impact factor: 2.000

3.  Anticentromere antibody in primary biliary cirrhosis.

Authors:  R M Bernstein; M E Callender; J M Neuberger; G R Hughes; R Williams
Journal:  Ann Rheum Dis       Date:  1982-12       Impact factor: 19.103

4.  Effects of cisapride on oesophageal transit of solids in patients with progressive systemic sclerosis.

Authors:  S J Wang; J L La; D Y Chen; Y H Chen; T Y Hsieh; W Y Lin
Journal:  Clin Rheumatol       Date:  2002-02       Impact factor: 2.980

5.  Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee.

Authors: 
Journal:  Arthritis Rheum       Date:  1980-05

6.  Assessment of intestinal permeability and orocecal transit time in patients with systemic sclerosis: analysis of relationships with epidemiologic and clinical parameters.

Authors:  Luigi Caserta; Laura de Magistris; Mario Secondulfo; Giancarlo Caravelli; Gabriele Riegler; Giovanna Cuomo; Salvatore D'Angelo; Caterina Naclerio; Gabriele Valentini; Romano Carratù
Journal:  Rheumatol Int       Date:  2003-02-15       Impact factor: 2.631

Review 7.  Gastrointestinal motility disorders in scleroderma.

Authors:  R W Sjogren
Journal:  Arthritis Rheum       Date:  1994-09

8.  Malabsorption caused by coeliac disease in patients who have scleroderma.

Authors:  C Marguerie; S Kaye; T Vyse; C Mackworth-Young; M J Walport; C Black
Journal:  Br J Rheumatol       Date:  1995-09

9.  Impaired rectoanal inhibitory response in scleroderma (systemic sclerosis): an association with fecal incontinence.

Authors:  Gregory J Heyt; Mina K Oh; Nazanin Alemzadeh; Susie Rivera; Sergio A Jimenez; Satish Rattan; Sidney Cohen; Anthony J Dimarino
Journal:  Dig Dis Sci       Date:  2004-06       Impact factor: 3.199

10.  Effects of cisapride on colonic transit in patients with progressive systemic sclerosis.

Authors:  S-J Wang; J-L Lan; J-L Lan; D-Y Chen; Y-H Chen; T-Y Hsieh; W-Y Lin
Journal:  Clin Rheumatol       Date:  2002-08       Impact factor: 2.980

View more
  7 in total

1.  Profile of gastrointestinal involvement in patients with systemic sclerosis.

Authors:  T Schmeiser; P Saar; D Jin; M Noethe; A Müller; N Soydan; P D Hardt; C Jaeger; O Distler; E Roeb; R G Bretzel; U Müller-Ladner
Journal:  Rheumatol Int       Date:  2011-07-19       Impact factor: 2.631

2.  Early endoscopy in systemic sclerosis without gastrointestinal symptoms.

Authors:  Rene Thonhofer; Cornelia Siegel; Markus Trummer; Winfried Graninger
Journal:  Rheumatol Int       Date:  2010-08-14       Impact factor: 2.631

Review 3.  Points to consider for clinical trials of the gastrointestinal tract in systemic sclerosis.

Authors:  Daniel E Furst; Yolanda Braun-Moscovic; Dinesh Khanna
Journal:  Rheumatology (Oxford)       Date:  2017-09-01       Impact factor: 7.580

Review 4.  Gastrointestinal manifestations of systemic sclerosis.

Authors:  Robyn Domsic; Kenneth Fasanella; Klaus Bielefeldt
Journal:  Dig Dis Sci       Date:  2007-10-13       Impact factor: 3.199

5.  High risk of gastrointestinal hemorrhage in patients with systemic sclerosis.

Authors:  Yi-Ting Lin; Yun-Shiuan Chuang; Jiunn-Wei Wang; Ping-Hsun Wu
Journal:  Arthritis Res Ther       Date:  2019-12-26       Impact factor: 5.156

6.  Distinguishing between limited systemic scleroderma-associated pseudo-obstruction and peritoneal dissemination.

Authors:  Susumu Saigusa; Yasuhiro Inoue; Masaki Ohi; Hiroki Imaoka; Ryo Uratani; Minako Kobayashi; Masato Kusunoki
Journal:  Surg Case Rep       Date:  2015-02-24

7.  Upper gastrointestinal involvement in systemic sclerosis: Findings in a real-life setting.

Authors:  Ana Petcu; Linda Jessica Ghib; Simona Mihaela Grad; Cornelia Popovici; Liliana Rogojan; Nicolae Voicu Rednic; Simona Rednic
Journal:  Exp Ther Med       Date:  2019-10-24       Impact factor: 2.447

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.